Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cladribine + cytarabine + venetoclax
- Development stage
- Phase 2
- Lead developer
- Johnson & Johnson
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A combination chemotherapy regimen consisting of cladribine, cytarabine, and venetoclax. This regimen is primarily used in the treatment of acute myeloid leukemia (AML), particularly in patients who have relapsed or become refractory to standard treatments such as venetoclax plus hypomethylating agents. The combination works through multiple mechanisms to target leukemic cells, with cladribine and cytarabine interfering with DNA synthesis and repair, while venetoclax promotes apoptosis by inhibiting BCL-2. This combination has shown promising efficacy, particularly in difficult-to-treat cases of AML.
- Other names
- CAV
02
Targets
BCL2L1 (B-cell lymphoma-extra large protein)DNMT (DNA methyltransferase)DNA polymerase familyRNR (Ribonucleotide reductase)BCL-2 (BCL-2 family)
Beyond the preview
Go deeper on cladribine + cytarabine + venetoclax.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cladribine + cytarabine + venetoclax.